Stock Information
Protagonist Therapeutics Inc (PTGX)
Ticker Symbol: PTGX
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $5,756.44 mil
Piotroski score: 3
PE Ratio: N/A
EPS (TTM): -2.0426
Revenue (TTM): $0.72 M
Dividend Yield: N/A%
ROE: -19.89%
Latest News
-
Goldman Sachs Maintains Neutral on Protagonist Therapeutics, Raises Price Target to $95
Tue, Mar 3, 2026 10:56 AM
-
Takeda And Protagonist Say FDA Grants Priority Review For Rusfertide As Potential First-In-Class Therapy For Polycythemia Vera, Backed By Phase 3 VERIFY Data
Mon, Mar 2, 2026 4:20 AM
-
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts
Thu, Feb 26, 2026 5:00 PM
-
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $100
Thu, Feb 26, 2026 2:21 PM
-
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $113
Thu, Feb 26, 2026 11:16 AM
-
Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $112
Thu, Feb 26, 2026 10:53 AM
-
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways
Wed, Feb 25, 2026 5:50 PM
-
Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate
Wed, Feb 25, 2026 5:50 PM
Key Financials
Financial data not available
